ClinicalTrials.gg
CompletedNCT01646021Updated Jan 19, 2018Results posted

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

A Phase 3 interventional study of Ibrutinib and Temsirolimus in Mantle Cell Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 98 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-19.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 45 studies testing ibrutinib in Lymphoma, Mantle-Cell — 2 open to participants now, 16 under way, 2 of them phase 3. ibrutinib · Lymphoma, Mantle-Cell.

Enrollment
4th of 45
280 · median 39
Started
2012
with 1 other
Phase 3
6 of 45
1 open now
Registered
6th of 45
by date
Lead sponsor
6 of 45
Janssen Research & Development, LLC

Among the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, this one is the 4th largest by enrollment, is one of 2 that started in 2012, is one of 6 in phase 3, and was the 6th registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

2 of the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who received at least 1 prior chemotherapy regimen.

Read the detailed description

This is a randomized (individuals assigned to study treatment by chance), open-label (identity of assigned study drug will be known), study to evaluate the efficacy and safety of ibrutinib when compared with temsirolimus in patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 1 prior rituximab-containing chemotherapy regimen. Approximately 280 eligible patients will be randomly assigned in a 1:1 ratio and stratified (grouped) by the number of prior lines of therapy (1 or 2 versus >=3) and simplified MCL International Prognostic Index criteria to receive either ibrutinib by mouth (Treatment Arm A) or temsirolimus intravenous infusion (Treatment Arm B). The study will consist of screening, treatment, and posttreatment phases. Data will be collected on disease response to the treatment, progression-free survival, overall survival, subsequent anti-MCL therapies, patient reported outcomes, and medical resource utilization. Tumor samples, blood collected at multiple time points, and a bone marrow aspirate will be evaluated to identify markers predictive of response or resistance to ibrutinib. Serial pharmacokinetic (study of what the body does to a drug) samples will be collected as detailed in the protocol. Safety will be monitored throughout the study. Disease evaluations will be performed every 9 weeks for up to 15 months from the start of study drug, and every 24 weeks thereafter, until disease progression, death, or the clinical cutoff, whichever comes first. Patients who receive treatment with temsirolimus and have disease progression (confirmed by an Independent Review Committee) may be eligible to crossover and receive treatment with ibrutinib 560 mg orally, daily, on a 21-day cycle until disease progression, unacceptable toxicity, or study end. Data will be analyzed up to 3 years after the last patient is enrolled for the final follow-up.

03

Conditions studied

  • Mantle Cell Lymphoma

Keywords

  • Mantle cell lymphoma
  • Relapsed mantle cell lymphoma
  • Refractory mantle cell lymphoma
  • Ibrutinib
  • Bruton's tyrosine kinase inhibitor
  • Temsirolimus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of mantle cell lymphoma (MCL)
  • Received at least 1 prior rituximab-containing chemotherapy regimen (separate are defined as single or combination therapies that are either separated by disease progression or by a > 6 month treatment-free interval)
  • Documented relapse or disease progression following the last anti-MCL treatment
  • At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma
  • performance status grade 0 or 1
  • Protocol-defined hematology and biochemistry laboratory values

Exclusion criteria

Exclusion Criteria:

  • Prior nitrosoureas within 6 weeks, chemotherapy within 3 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy or other agents within 3 weeks, or major surgery within 4 weeks of randomization
  • Prior treatment with temsirolimus, other mTOR inhibitors, ibrutinib, or other Bruton's tyrosine kinase (BTK) inhibitors
  • Known central nervous system lymphoma
  • Received an or autologous hematopoietic stem cell transplant \<=6 months from the date of randomization and on therapy or have evidence of active
  • Diagnosed or treated for other than MCL, except: malignancy treated with curative intent and with no known active disease present for >=3 years before randomization, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, adequately treated cervical carcinoma in situ without evidence of disease
  • History of stroke or intracranial hemorrhage within 6 months prior to randomization
  • Requires anticoagulation with warfarin or equivalent vitamin K antagonist
  • Requires treatment with strong inhibitor
  • cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the Functional Classification
  • Known history of (HIV) or active virus (HCV) or active virus (HBV) infection or any uncontrolled active systemic infection requiring intravenous antibiotics
  • Woman who is pregnant or breast-feeding
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (actual)

Study arms

  • Experimental
    Ibrutinib

    Drug: Ibrutinib

  • Experimental
    Temsirolimus

    Drug: Temsirolimus

Interventions

  • 560 mg once daily continuous (without interruption) by mouth for 21-day cycles

  • 175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycle

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the duration in months from the date of randomization to the date of progression disease (PD) or relapse from complete response (CR) or death whichever was reported first and was assessed based on the investigator assessment. Revised Response Criteria for Malignant Lymphoma categorizes the response of the treatment of a patient's tumour to CR (the disappearance of all evidence of disease), Relapsed Disease or PD (Any new lesion or increase by greater than or equal to \[\>=\] 50 percent \[%\] of previously involved sites from nadir).

    Time frame: Time from the date of randomization until the date of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death, whichever occurred first (approximately 48 months)

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieved either CR or PR as best overall response based on the investigator assessment. CR is Disappearance of all target lesions while PR is greater than or equal to 30 % decrease in the sum of the longest diameter of target lesions and Overall Response (OR) is sum of CR and PR.

    Time frame: Approximately up to 48 months

  2. Overall Survival (OS)

    Overall survival (OS) was defined as the interval between the date of randomization and the date of death from any cause.

    Time frame: Approximately up to 48 months

  3. Duration of Response

    Duration of response (CR or PR), defined as the duration in days from the date of initial response to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death. The analysis was based on the investigator assessment.

    Time frame: Approximately up to 48 months

  4. Time-to-Next Treatment

    Time to next treatment was measured from the date of randomization to the start date of any anti-neoplastic treatment subsequent to study treatment.

    Time frame: Approximately up to 48 months

  5. Progression-Free Survival 2

    Progression-free survival 2 defined as the time interval between the date of randomization and date of event, defined as progressive disease as assessed by investigator that started after the next line of subsequent anti-neoplastic therapy (including cross-over to ibrutinib), death from any cause, or the start of the second subsequent anti-neoplastic therapy if no progressive disease was recorded after the first subsequent anti-neoplastic therapy.

    Time frame: Approximately up to 48 months

  6. Time to Worsening in the Lymphoma Sub Scale of Functional Assessment of Cancer Therapy- Lymphoma (FACT-Lym)

    Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening. Worsening was defined by a 5-point decrease from baseline. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life.

    Time frame: Approximately up to 48 months

  7. Number of Participants Affected With Treatment-emergent Adverse Events

    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Time from first dose of study drug until the last dose date + 30 days or the start of a subsequent anti-neoplastic therapy, whichever occur earlier (Approximately up to 4 years)

Other outcomes

  1. Time to Response

    Time to response for participants with CR/PR, defined as the interval between the date of randomization and date of initial documentation of response.

    Time frame: Approximately up to 2.8 years

  2. Extent of Exposure of Time

    Extent of exposure is defined as the duration of the treatment administered during the study. Duration of exposure is calculated as the number of months between the start and end of treatment.

    Time frame: Approximately up to 46.8 months

  3. One Year Survival Rate

    One -year survival rate, defined as the proportion of participants who were alive 1 year after randomization.

    Time frame: Month 12

  4. Area Under the Plasma Concentration of Ibrutinib During Steady State (AUC-ss)

    The AUC-ss is the area under the plasma concentration time curve observed during steady state.

    Time frame: Cycle 1 and 2 (Day 1): Predose, 1, 2, 4 hr. postdose; Cycle 3 (day 1): Predose (Each cycle is of 21 days)

  5. Number of Participants With Biomarkers That Alter B-cell Receptor (BCR) Signaling or Activate Alternative Signaling Pathways and to Explore Their Association With Response or Resistance to Ibrutinib

    Biomarker evaluations to identify markers altering BCR signaling or activate alternative signaling pathways and explore their association with response or resistance to ibrutinib. Next-generation sequencing at baseline identifies possible primary resistance mutations and those found only at progression are acquired mutations on therapy.

    Time frame: Approximately up to 28.2 months

  6. Number of Hospitalizations Reported Related Medical Resource Utilization Information (MRUI)

    Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.

    Time frame: Approximately up to 28.2 months

  7. Number of Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)

    Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.

    Time frame: Approximately up to 28.2 months

  8. Days of Hospitalization and Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)

    Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.

    Time frame: Approximately up to 28.2 months

  9. The Mean Change From Baseline in Euro QoL Five-Dimension (EQ-5D-5L) Scores for Each Post Baseline Assessment

    The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, using 5 levels (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and possible total score range -0.594 to 1; higher score indicates a better health state.

    Time frame: Baseline, Cycle 2, 3, 4, 5, 6, 7, 8, 11, 14, 17, 20, 28, 36 and End of treatment (approximately up to 23 months)

07

Results

Posted Mar 1, 2017

Participant flow

Participant flow — Overall Study
MilestoneIbrutinibTemsirolimus
Started139141
Treated139139
Completed00
Not completed139141
Withdrew: Death7783
Withdrew: Study terminated by sponsor5041
Withdrew: Lost to follow-up22
Withdrew: Withdrawal by subject1015

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS is defined as the duration in months from the date of randomization to the date of progression disease (PD) or relapse from complete response (CR) or death whichever was reported first and was assessed based on the investigator assessment. Revised Response Criteria for Malignant Lymphoma categorizes the response of the treatment of a patient's tumour to CR (the disappearance of all evidence of disease), Relapsed Disease or PD (Any new lesion or increase by greater than or equal to \[\>=\] 50 percent \[%\] of previously involved sites from nadir).

Time frame:
Time from the date of randomization until the date of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death, whichever occurred first (approximately 48 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsIbrutinibTemsirolimus
Progression Free Survival (PFS)15.6 (10.6 to 25.1)6.2 (4.2 to 7.8)
Statistical analysis
  • Ibrutinib vs Temsirolimus · Log Rank · p = < 0.0001 · Hazard ratio (hr): 0.45 · 95% CI 0.35 to 0.60
SecondaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants who achieved either CR or PR as best overall response based on the investigator assessment. CR is Disappearance of all target lesions while PR is greater than or equal to 30 % decrease in the sum of the longest diameter of target lesions and Overall Response (OR) is sum of CR and PR.

Time frame:
Approximately up to 48 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsIbrutinibTemsirolimus
Overall Response Rate (ORR)77.046.8
SecondaryOverall Survival (OS)

Overall survival (OS) was defined as the interval between the date of randomization and the date of death from any cause.

Time frame:
Approximately up to 48 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsIbrutinibTemsirolimus
Overall Survival (OS)30.3 (19.1 to 42.1)23.5 (13.0 to 30.7)
Statistical analysis
  • Ibrutinib vs Temsirolimus · Log Rank · p = = 0.0621 · Hazard ratio (hr): 0.74 · 95% CI 0.54 to 1.02
SecondaryDuration of Response

Duration of response (CR or PR), defined as the duration in days from the date of initial response to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death. The analysis was based on the investigator assessment.

Time frame:
Approximately up to 48 months
Reported as:
Median · Months
Duration of Response
MonthsIbrutinibTemsirolimus
Duration of Response23.1 (16.2 to 28.1)6.3 (4.7 to 8.6)
SecondaryTime-to-Next Treatment

Time to next treatment was measured from the date of randomization to the start date of any anti-neoplastic treatment subsequent to study treatment.

Time frame:
Approximately up to 48 months
Reported as:
Median · Months
Time-to-Next Treatment
MonthsIbrutinibTemsirolimus
Time-to-Next Treatment31.8 (23.3 to NA)11.6 (8.0 to 13.3)
SecondaryProgression-Free Survival 2

Progression-free survival 2 defined as the time interval between the date of randomization and date of event, defined as progressive disease as assessed by investigator that started after the next line of subsequent anti-neoplastic therapy (including cross-over to ibrutinib), death from any cause, or the start of the second subsequent anti-neoplastic therapy if no progressive disease was recorded after the first subsequent anti-neoplastic therapy.

Time frame:
Approximately up to 48 months
Reported as:
Median · Months
Progression-Free Survival 2
MonthsIbrutinibTemsirolimus
Progression-Free Survival 226.2 (17.2 to 32.4)15.4 (10.2 to 21.3)
SecondaryTime to Worsening in the Lymphoma Sub Scale of Functional Assessment of Cancer Therapy- Lymphoma (FACT-Lym)

Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening. Worsening was defined by a 5-point decrease from baseline. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life.

Time frame:
Approximately up to 48 months
Reported as:
Median · Weeks
Time to Worsening in the Lymphoma Sub Scale of Functional Assessment of Cancer Therapy- Lymphoma (FACT-Lym)
WeeksIbrutinibTemsirolimus
Time to Worsening in the Lymphoma Sub Scale of Functional Assessment of Cancer Therapy- Lymphoma (FACT-Lym)NA (81.4 to NA)10.6 (6.6 to 15.3)
SecondaryNumber of Participants Affected With Treatment-emergent Adverse Events

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Time from first dose of study drug until the last dose date + 30 days or the start of a subsequent anti-neoplastic therapy, whichever occur earlier (Approximately up to 4 years)
Reported as:
Count of participants · Participants
Number of Participants Affected With Treatment-emergent Adverse Events
ParticipantsIbrutinibTemsirolimus
Number of Participants Affected With Treatment-emergent Adverse Events139138
Other pre-specifiedTime to Response

Time to response for participants with CR/PR, defined as the interval between the date of randomization and date of initial documentation of response.

Time frame:
Approximately up to 2.8 years
Reported as:
Median · Months
Time to Response
MonthsIbrutinibTemsirolimus
Time to Response2.15 (0.5 to 10.4)2.14 (0.9 to 12.0)
Other pre-specifiedExtent of Exposure of Time

Extent of exposure is defined as the duration of the treatment administered during the study. Duration of exposure is calculated as the number of months between the start and end of treatment.

Time frame:
Approximately up to 46.8 months
Reported as:
Median · Months
Extent of Exposure of Time
MonthsIbrutinibTemsirolimus
Extent of Exposure of Time14.39 (0.0 to 46.8)3.02 (0.0 to 31.4)
Other pre-specifiedOne Year Survival Rate

One -year survival rate, defined as the proportion of participants who were alive 1 year after randomization.

Time frame:
Month 12
Reported as:
Number · Proportion of participants
One Year Survival Rate
Proportion of participantsIbrutinibTemsirolimus
One Year Survival Rate0.68 (0.59 to 0.75)0.61 (0.52 to 0.69)
Other pre-specifiedArea Under the Plasma Concentration of Ibrutinib During Steady State (AUC-ss)

The AUC-ss is the area under the plasma concentration time curve observed during steady state.

Time frame:
Cycle 1 and 2 (Day 1): Predose, 1, 2, 4 hr. postdose; Cycle 3 (day 1): Predose (Each cycle is of 21 days)
Reported as:
Mean · nanogram*hour per milliliter (ng*h/mL)
Area Under the Plasma Concentration of Ibrutinib During Steady State (AUC-ss)
nanogram*hour per milliliter (ng*h/mL)Ibrutinib
Area Under the Plasma Concentration of Ibrutinib During Steady State (AUC-ss)561.6 ± 448
Other pre-specifiedNumber of Participants With Biomarkers That Alter B-cell Receptor (BCR) Signaling or Activate Alternative Signaling Pathways and to Explore Their Association With Response or Resistance to Ibrutinib

Biomarker evaluations to identify markers altering BCR signaling or activate alternative signaling pathways and explore their association with response or resistance to ibrutinib. Next-generation sequencing at baseline identifies possible primary resistance mutations and those found only at progression are acquired mutations on therapy.

Time frame:
Approximately up to 28.2 months
Reported as:
Number · Participants
Number of Participants With Biomarkers That Alter B-cell Receptor (BCR) Signaling or Activate Alternative Signaling Pathways and to Explore Their Association With Response or Resistance to Ibrutinib
ParticipantsIbrutinibTemsirolimus
Number of Participants With Biomarkers That Alter B-cell Receptor (BCR) Signaling or Activate Alternative Signaling Pathways and to Explore Their Association With Response or Resistance to Ibrutinib6153
Other pre-specifiedNumber of Hospitalizations Reported Related Medical Resource Utilization Information (MRUI)

Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.

Time frame:
Approximately up to 28.2 months
Reported as:
Mean · Hospitalizations
Number of Hospitalizations Reported Related Medical Resource Utilization Information (MRUI)
HospitalizationsIbrutinibTemsirolimus
Number of Hospitalizations Reported Related Medical Resource Utilization Information (MRUI)3.1 ± 4.62.8 ± 4.3
Other pre-specifiedNumber of Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)

Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.

Time frame:
Approximately up to 28.2 months
Reported as:
Mean · Emergency room visits
Number of Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)
Emergency room visitsIbrutinibTemsirolimus
Number of Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)1.2 ± 0.41.2 ± 0.4
Other pre-specifiedDays of Hospitalization and Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)

Medical resource utilization data associated with medical encounters related to disease was reported for all participants throughout the study.

Time frame:
Approximately up to 28.2 months
Reported as:
Mean · Days
Days of Hospitalization and Emergency Room Visits Reported Related Medical Resource Utilization Information (MRUI)
DaysIbrutinibTemsirolimus
Mean days of hospitalization19.7 ± 20.520.3 ± 22.4
Mean days of emergency room visits1.8 ± 1.31.6 ± 1.3
Other pre-specifiedThe Mean Change From Baseline in Euro QoL Five-Dimension (EQ-5D-5L) Scores for Each Post Baseline Assessment

The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression, using 5 levels (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and possible total score range -0.594 to 1; higher score indicates a better health state.

Time frame:
Baseline, Cycle 2, 3, 4, 5, 6, 7, 8, 11, 14, 17, 20, 28, 36 and End of treatment (approximately up to 23 months)
Reported as:
Mean · Units on scale
The Mean Change From Baseline in Euro QoL Five-Dimension (EQ-5D-5L) Scores for Each Post Baseline Assessment
Units on scaleIbrutinibTemsirolimus
Baseline0.7 ± 0.20.7 ± 0.2
Change at Cycle 20.0 ± 0.20.0 ± 0.2
Change at Cycle 30.1 ± 0.2-0.1 ± 0.2
Change at Cycle 40.0 ± 0.20.0 ± 0.3
Change at Cycle 50.0 ± 0.20.0 ± 0.2
Change at Cycle 60.1 ± 0.20.0 ± 0.2
Change at Cycle 70.0 ± 0.20.0 ± 0.2
Change at Cycle 80.0 ± 0.20.0 ± 0.2
Change at Cycle 110.0 ± 0.20.0 ± 0.2
Change at Cycle 140.0 ± 0.20.0 ± 0.1
Change at Cycle 170.0 ± 0.20.0 ± 0.2
Change at Cycle 200.0 ± 0.20.0 ± 0.2
Change at Cycle 28-0.1 ± 0.20.1 ± 0.2
Change at Cycle 360.0 ± 0.3-0.1 ± 0.2
Change at End of treatment0.0 ± 0.2-0.1 ± 0.3

Adverse events

Collected over Approximately up to 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib130/139 (93.5%)79/139 (56.8%)130/139 (93.5%)
Temsirolimus137/139 (98.6%)83/139 (59.7%)137/139 (98.6%)
Most frequent serious events
Showing 10 of 180
Most frequent serious events
EventIbrutinibTemsirolimus
PneumoniaInfections and infestations16/13912/139
Atrial FibrillationCardiac disorders7/1392/139
PyrexiaGeneral disorders3/1397/139
SepsisInfections and infestations6/1395/139
DyspnoeaRespiratory, thoracic and mediastinal disorders6/1395/139
Pleural EffusionRespiratory, thoracic and mediastinal disorders6/1390/139
AnaemiaBlood and lymphatic system disorders4/1395/139
ThrombocytopeniaBlood and lymphatic system disorders5/1393/139
Abdominal PainGastrointestinal disorders5/1391/139
General Physical Health DeteriorationGeneral disorders3/1395/139
Most frequent other events
Showing 10 of 72
Most frequent other events
EventIbrutinibTemsirolimus
ThrombocytopeniaBlood and lymphatic system disorders25/13977/139
AnaemiaBlood and lymphatic system disorders27/13957/139
DiarrhoeaGastrointestinal disorders45/13942/139
FatigueGeneral disorders31/13940/139
NeutropeniaBlood and lymphatic system disorders21/13936/139
Oedema PeripheralGeneral disorders19/13933/139
CoughRespiratory, thoracic and mediastinal disorders31/13931/139
EpistaxisRespiratory, thoracic and mediastinal disorders13/13931/139
NauseaGastrointestinal disorders20/13930/139
StomatitisGastrointestinal disorders4/13928/139

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IbrutinibTemsirolimusTotal
<=18 years000
Between 18 and 65 years5354107
>=65 years8687173
Age, Continuous
Age, Continuous(years)IbrutinibTemsirolimusTotal
Mean66.7 ± 8.6867.1 ± 9.8366.9 ± 9.26
Sex/Gender, Customized
Sex/Gender, Customized(participants)IbrutinibTemsirolimusTotal
Female393372
Male100108208
Region of Enrollment
Region of Enrollment(participants)IbrutinibTemsirolimusTotal
Belgium71017
Brazil51015
Canada639
Colombia347
Czech Republic7714
Germany121123
Spain51419
France5510
United Kingdom111627
Hungary5712
Ireland213
Italy6814
South Korea11314
Mexico112
Netherlands202
Poland91423
Portugal336
Russian Federation181129
Sweden10818
Taiwan516
Ukraine6410
08

Study locations

98 sites
  • Antwerpen, Belgium
  • Brugge, Belgium
  • Brussels, Belgium
  • Edegem, Belgium
  • Gent, Belgium
  • Leuven, Belgium
  • Wilrijk, Belgium
  • Goiânia, Brazil
  • Porto Alegre, Brazil
  • Ribeirão Preto, Brazil
  • Rio De Janeiro, Brazil
  • Sao Paulo, Brazil
  • Edmonton, Alberta, Canada
  • Ottawa, Ontario, Canada
  • Montreal, Quebec, Canada
  • Temuco, Chile
  • Bogota, Colombia
  • Medellin, Colombia
  • Brno, Czechia
  • Praha 10, Czechia
  • Praha 2, Czechia
  • Mulhouse, France
  • Paris Cedex 15, France
  • Paris, France
  • Pessac, France
  • Villejuif, France
  • Berlin, Germany
  • Essen, Germany
  • Heidelberg, Germany
  • Homburg, Germany
  • Kiel, Germany
  • Koln, Germany
  • Mainz, Germany
  • Munchen, Germany
  • Ulm, Germany
  • Budapest, Hungary
  • Debrecen, Hungary
  • Pécs N/A, Hungary
  • Szeged, Hungary
  • Dublin, Ireland
  • Goyang-Si, Korea, Republic of
  • Seoul, Korea, Republic of
  • Monterrey, Mexico
  • Oaxaca, Mexico
  • Queretaro, Mexico
  • Amsterdam, Netherlands
  • Rotterdam, Netherlands
  • Brzozow, Poland
  • Chorzow, Poland
  • Gdansk, Poland
  • Krakow, Poland
  • Opole, Poland
  • Slupsk, Poland
  • Wroclaw, Poland
  • Coimbra, Portugal
  • Lisboa, Portugal
  • Lisbon, Portugal
  • Porto, Portugal
  • Chelyabinsk, Russian Federation
  • Ekaterinburg, Russian Federation
  • Krasnodar, Russian Federation
  • Moscow N/A, Russian Federation
  • Moscow, Russian Federation
  • Nizhny Novgorod, Russian Federation
  • Obninsk, Russian Federation
  • Rostov-Na-Donu, Russian Federation
  • Saint Petersburg, Russian Federation
  • Sochi, Russian Federation
  • St-Petersburg, Russian Federation
  • St. Petersburg, Russian Federation
  • Syktyvkar, Russian Federation
  • Barcelona, Spain
  • Madrid, Spain
  • Palma De Mallorca, Spain
  • Salamanca, Spain
  • Valencia, Spain
  • Göteborg, Sweden
  • Lund, Sweden
  • Stockholm, Sweden
  • Umeå, Sweden
  • Uppsala, Sweden
  • Tainan, Taiwan
  • Taipei, Taiwan
  • Taoyuan, Taiwan
  • Cherkassy, Ukraine
  • Dnepropetrovsk, Ukraine
  • Donetsk, Ukraine
  • Khmelnitskiy, Ukraine
  • Kiev, Ukraine
  • Lviv, Ukraine
  • Birmingham, United Kingdom
  • Harrow, United Kingdom
  • Leeds, United Kingdom
  • Liverpool, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
  • Plymouth, United Kingdom
  • Southampton, United Kingdom
09

References and documents

Publications

  • Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017 Oct;102(10):1796-1805. doi: 10.3324/haematol.2017.171041. Epub 2017 Jul 27. PubMed 28751558 ↗
  • Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7. Erratum In: Lancet. 2016 Feb 20;387(10020):750. PubMed 26673811 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Jun 2015, 29 months.

Results were first posted in Mar 2017, 1 year 8 months after primary completion.

Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2012
First posted
Jul 20, 2012
StartActual
Dec 10, 2012
Primary completionActual
Jun 5, 2015
CompletionActual
Dec 15, 2016
Results first posted
Mar 1, 2017
Last update
Jan 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01646021
Collaborators
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Jul 20, 2012
Start date
Dec 10, 2012
Primary completion
Jun 5, 2015
Completion
Dec 15, 2016
Results posted
Mar 1, 2017
Last update
Jan 19, 2018

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Temsirolimus

Start the discussion